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Chronic inflammation takes part in the pathogenesis of some malignancies of the 
gastrointestinal tract including colorectal (CRC), gastric, and esophageal cancers. The 
use of ω3 polyunsaturated fatty acid (ω3-PUFA) supplements for chemoprevention 
or adjuvant therapy of gastrointestinal cancers is being investigated in recent years. 
Most evidence has been reported in CRC, although their protective role has also been 
reported for Helicobacter pylori-induced gastric cancer or Barrett’s esophagus-derived 
adenocarcinoma. Studies based on ω3-PUFA supplementation in animal models of familial 
adenomatous polyposis (FAP) and CRC revealed positive effects on cancer prevention, 
reducing the number and size of tumors, down-regulating arachidonic acid-derived 
eicosanoids, upregulating anti-oxidant enzymes, and reducing lipid peroxidation, whereas 
contradictory results have been found in induced colitis and colitis-associated cancer. 
Beneficial effects have also been found in FAP and ulcerative colitis patients. Of special 
interest is their positive effect as adjuvants on radio- and chemo-sensitivity, specificity, 
and prevention of treatment complications. Some controversial results obtained in CRC 
might be justified by different dietary sources, extraction and preparation procedures of 
ω3-PUFAs, difficulties on filling out food questionnaires, daily dose and type of PUFAs, 
adenoma subtype, location of CRC, sex differences, and genetic factors. Studies 
using animal models of inflammatory bowel disease have confirmed that exogenous 
administration of active metabolites derived from PUFAs called pro-resolving mediators 
like lipoxin A4, arachidonic acid-derived, resolvins derived from eicosapentaenoic (EPA), 
docosahexaenoic (DHA), and docosapentaenoic (DPA) acids as well as maresin 1 and 
protectins DHA- and DPA-derived improve disease and inflammatory outcomes without 
causing immunosuppression or other side effects.
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INTRODUCTION
Colorectal, gastric, and esophageal cancers are among the most 
commonly diagnosed cancers worldwide, as well as the more 
frequent causes of cancer death. Nowadays, chronic inflammation, 
caused by failure of the necessary self-limited acute inflammatory 
response, which prevents from the complete resolution of the 
inflammatory process, is accepted as one of the main predisposing 
factors to cancer (Balkwill et al., 2005; Hanahan and Weinberg, 
2011). Although CRC cases are mainly “sporadic,” there are 
several situations in which increased risk has been reported, 
including genetic and inflammatory disorders. These disorders 
include inherited mutations in the APC gene in FAP, those related 
to mismatch DNA repair in Lynch syndrome (Ma et al., 2018), or 
the presence of inflammatory bowel disease (Saleh and Trinchieri, 
2011; Dulai et al., 2016). Other factors contributing to chronic 
inflammation are bacterial infections, such as Helicobacter pylori 
(H. pylori) infection related to gastric cancer, or non-infectious 
causes of inflammation, such as esophageal reflux, the main 
driver of Barrett’s esophagus and esophageal adenocarcinoma. 
In addition, other factors include reduced physical activity, an 
unbalanced diet like those rich in saturated fats, low fiber, red 
and processed meat, overweight or obesity, alcohol consumption, 
or smoking, which have been associated with chronic low-grade 
inflammation (parainflammation) and increased cancer risk too 
(Baan et al., 2007; Aune et al., 2011; Park et al., 2011; Perera et al., 
2012; Aune et al., 2013; Schlesinger et al., 2017; Vieira et al., 
2017; Abar et al., 2018). During the inflammation onset phase, 
endogenous lipid mediators (LMs) like prostaglandins (PGs) and 
leukotrienes (LTs) are released from arachidonic acid (AA) acting 
as go signals for inflammation, increasing vascular permeability 
that enables polymorphonuclear leukocyte (PMN) infiltration 
into the damaged tissue, and afterwards, prostaglandins 
(PGE2 and PGD2) acting as stop signals mark the end of acute 
inflammation and the beginning of LM-class switching process 
by transcriptional activation of 15-lipoxygenase (15-LOX) in 
neutrophils and then producing the first class of endogenous 
specialized pro-resolving lipid mediator (SPM), AA-derived, 
called lipoxins (LXs), stop-and-go signals for inflammation 
and resolution phases (Qiu et al., 2001; Nathan, 2002; Serhan, 
2007). After LXs, other types of endogenous SPMs derived from 
ω3 polyunsaturated fatty acids (ω3-PUFAs) presenting as LXs, 
both anti-inflammatory and pro-resolving properties (Takano 
et al., 1997; Devchand et al., 2005; Serhan, 2007) named resolvins 
(Rvs), protectins (PDs), and maresins (MaRs), are produced 
through transcellular routes by LOX activity, orchestrating the 
resolution of inflammation during an active process including 
sequestration of pro-inflammatory cytokines, clearance of 
neutrophils, phagocytosis of apoptotic neutrophils, and removal 
of inflammatory debris and restoring tissue (Serhan et al., 2007). 
Classical anti-inflammatory aspirin treatment, apart from 
inhibiting PG biosynthesis, can also generate epimeric-aspirin-
triggered LXs or Rvs from PUFAs (ATL/AT-Rv) with the same 
protective actions and longer bioactivities (Gewirtz et al., 2002; 
Serhan and Chiang, 2008; Serhan, 2014). SPMs exert potent local 
bioactions and afterwards are rapidly inactivated, presenting 
short half-lives. For this reason, the elucidation of their chemical 
structures has provided a model to be used for designing 
mimetics analogs with reinforced stability, effectiveness, half-life, 
and an appropriate bioavailability, to be used as pharmacologic 
molecules to rescue resolution in inflammatory diseases (Serhan 
and Chiang, 2008). Cancer prevention programs have already 
been implemented in most countries, but chemoprevention 
agents should be considered to be used alone or in combination 
with other treatments to improve resolution of inflammation and 
prevent cancer development, since once the cancer is present, 
actual treatments are associated with serious adverse effects and 
are not effective enough in advanced tumors.
SPMS IN THE RESOLUTION OF 
INFLAMMATORY BOWEL DISEASE. 
LESSON LEARNED FROM IBD ANIMAL 
MODELS
Inflammatory bowel disease (IBD) is a chronic disease of the 
gastrointestinal tract presenting two major forms, ulcerative 
colitis (UC) and Crohn’s disease (CD). UC is a relapsing non-
transmural inflammatory condition that affects only the colon 
(Baumgart and Sandborn, 2007), whereas CD runs with relapsing 
transmural injuries in several parts of the gastrointestinal tract 
from the mouth to the anus mainly due to a dysregulated immune 
response to host intestinal microbiota (Wallace et al., 2014). 
These disorders are associated with epithelial damage, leukocyte 
infiltration into the intestinal wall, and AA-cascade activation, 
increasing CRC risk. Increased risk has been described for bigger 
extension of inflammation, earlier onset, and longer time from 
diagnosis (Ekbom et al., 1990; Gillen et al., 1994; Munkholm, 
2003; Friedman et al., 2008; Lutgens et al., 2015).The most 
frequently used IBD models are those generated by induction 
with 2,4,6-trinitrobenzenesulphonic acid (TNBS) and dextran 
sodium sulfate (DSS) to resemble CD and UC, respectively 
(Morris et al., 1989; Bento et al., 2012).
Endogenous lipoxins, the only AA-derived SPMs (Claria 
and Serhan, 1995), are generated by LOX activity and act as 
antagonists of pro-inflammatory LTs. Oral administration of 
ATL analogs reduced weight loss and mortality in DSS and 
TNBS models and decreased colon injury, colon wall thickening, 
mucosal PMN infiltration, and mRNA and/or protein expression 
of pro-inflammatory mediators such as inducible nitric oxide 
synthase (iNOS), COX-2, macrophage inflammatory protein 2 
(MIP-2), tumor necrosis factor-alpha (TNFα), interleukin-2 (IL-
2), and IFNγ in TNBS model (Gewirtz et al., 2002; Fiorucci et al., 
2004) (Table 1).
Resolvins are endogenous LMs derived from EPA (RvE) 
and DHA (RvD). As LXs, synthetic RvE1 protects against IBD 
induction in animal models improving survival, body weight, 
histological scores of disease by decreasing PMN infiltration, 
and gene expression of TNF-α, IL-12, iNOS, and COX-2 in 
TNBS model (Arita et al., 2005) and by the induction of the 
intestinal epithelial expression of alkaline phosphatase (ALPI) 
and decreasing phosphorylation of NF-κB p65 Ser276 and 
mRNA expression of pro-inflammatory TNF-α, IL-1β, and 
ω3-PUFAs in the Gastrointestinal TractIrún et al.
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TABLE 1 | In vivo actions of synthetic pro-resolving lipid mediators (SPMs), ATL analogs and omega-3 acids in disease models.
Disease model Actions Mediator References




Gewirtz et al. (2002)
TNBS colitis • Reduces body weight loss
• Improves survival
• Reduces colon injury
• Reduces mucosal inflammation
• Reduces PMN infiltration
• Reduces mRNA levels: iNOS, COX-2, MIP-2
• Decreases protein levels: TNFα, IL-2, IFNγ
ZK-192
(ATL analog)
Fiorucci et al. (2004)
TNBS colitis • Reduces body weight loss
• Improves survival
• Reduces colon injury
• Reduces PMN infiltration
• Reduces mRNA levels: iNOS, COX-2, IL-12 p40, TNFα
Synthetic RvE1 Arita et al. (2005)
DSS colitis • Reduces body weight loss
• Reduces colon shortening
• Protects the epithelium and crypt architecture
• Improves disease activity index
• Induces colonic ALPI mRNA expression
• Reduces proinflammatory IL-1β and murine KC (IL-8 human 
homolog)
Synthetic RvE1 Campbell et al. (2010)
DSS colitis • Reduces body weight loss
• Reduces colon injury
• Improves disease activity index
• Reduces PMN infiltration
• Reduces NF-κB activity
• Reduces mRNA expression of TNFα, IL-1β, and IL-6 
Synthetic RvE1 Ishida et al. (2010)
DSS colitis • Reduces body weight loss
• Improves disease activity index
• Reduces colonic tissue damage
• Reduces PMN infiltration
• Reduces colonic protein levels of mediators of inflammatory cell 
recruitment TNFα, IL-1β, MIP-2, and CXCL1/KC
• Reduces NF-κB activity and mRNA expression
• Reduces mRNA expression adhesion molecules VCAM-1, ICAM-1, 
and LFA-1





Bento et al. (2011)
TNBS colitis • Reduces body weight loss
• Improves disease activity index
• Reduces colonic tissue damage





Bento et al. (2011)
DSS colitis • Reduces body weight loss
• Reduces colon shortening
• Improves disease activity index
• Reduces PMN infiltration
• Reduces colonic tissue damage
• Reduces NF-kB activity
• Decreases ICAM-1 mRNA expression
• Reduces IL-1β, TNFα, IL-6, and IFNγ in the acute colitis
• Reduces IL-1β, IL-6 in chronic colitis
Synthetic
MaR1
Marcon et al. (2013)
TNBS colitis • Reduces body weight loss
• Improves disease activity index
• Reduces colonic tissue damage
• Reduces PMN infiltration
Synthetic
MaR1
Marcon et al. (2013)
DSS colitis • Reduces colon shortening
• Reduces colonic tissue damage
• Reduces colon wall thickness
• Reduces pro-inflammatory TNFα, IL-1β, IL-6
• Reduces PMN infiltration
PD1n-3 DPA Gobbetti et al. (2017)
(Continued)
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TABLE 1 | Continued
Disease model Actions Mediator References
DSS colitis • Reduces colon shortening
• Reduces colonic tissue damage
• Reduces partially IL-1β
• Reduces PMN infiltration
RvD5n-3 DPA Gobbetti et al. (2017)
DSS colitis • Reduces body weight loss
• Reduces colonic tissue damage
• Improves disease activity index
• Reduces PMN infiltration





Chiu et al. (2012)
APCMin/+ FAP model • Reduces weight loss
• Reduces the number of tumors
• Reduces the size of tumors
• Increases tissue switch from AA to EPA
• Reduces tissue prostaglandin levels of PGE2 and 6- keto-PGF1
EPA ethyl ester Hansen Petrik et al. (2000)
APCMin/+ FAP model • Reduces weight loss
• Reduces lipid peroxidation
• High reduction in polyp number
• Reduces polyp load and size
• Increases tissue switch from AA to EPA
• Reduces COX-2 expression
• Reduces β-catenin nuclear translocation
• Reduces proliferation
• Increases apoptosis
EPA free fatty acid Fini et al. (2010)
NMU-colorectal 
model
• Reduces tumor incidence
• Increases antioxidative enzyme activities of SOD and GPx
• Reduces lipid peroxidation
Fish oil Kenar et al. (2008)
DSS colitis • Increases body weight loss
• Increases colon shortening
• Enhances inflammation
• Exacerbates colitis
• Decreases of adiponectin expression
Fish oil Matsunaga et al. (2008)
DSS colitis • Reduces body weight loss
• Reduces colon shortening
• Downregulates pro-inflammatory TNFα, COX-2, mPGES, TXAS
• Upregulates anti-inflammatory PGDS
• Restores the architecture of the colon epithelium
• Reduces inflammatory cell infiltration
• Reduces levels of LPO, protein carbonyl and ROS
• Increases antioxidant activities of GPx, GST and GR
Fish oil Sharma et al. (2019)
DSS colitis • Reduces colon shortening
• Reduces disease severity
• Reduces tissue levels of pro-inflammatory TNFα, IL-1β, and IL-6
• Decreases PMN infiltration
• Reduces NF-kB activity
• Decreases expression of COX-2 in colon 
EPA monoglyceride Morin et al. (2016)
DSS colitis
Fat-1 mouse
• Reduces body weight loss
• Reduces colon shortening
• Reduces colon damage
• Reduces PMN infiltration
• Produces RvE1, RvD3, NPD1, PD1, 17HDHA and 14-HDHA in colon
• Reduces NF-kB activity
• Decreases mRNA level of TNFα, iNOS, IL-1β
• Increases mRNA level of mucoprotective factors Tollip and TFF3
Endogenous conversion of ω6- into 
ω3-PUFAs
Hudert et al. (2006)
CAC model
Fat-1 mouse
• Reduces weight loss
• Reduces colon shortening
• Decreases inflammation severity and mucosal thickness
• Reduces tumor incidence
• Reduces tumor growth rate
• Reduces NF-kB activity
• Increases TGFβ mRNA expression
• Reduces iNOS mRNA expression 
Endogenous conversion of ω6- into 
ω3-PUFAs
Nowak et al. (2007)
(Continued)
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TABLE 1 | Continued
Disease model Actions Mediator References
CAC model
Fat-1 mouse
• Reduces tumor number
• Increases apoptosis
• Improves inflammation and ulceration scores
• Decreases ω6 PUFA-derived eicosanoids (PGE2, PGD2, PGE1 and 
12-HETE)
• Increases ω3 PUFA-derived eicosanoid (PGE3)
• Decreases CD3+, CD4+ T helper, and macrophage cell numbers 
in colon
Endogenous conversion of ω6- into 
ω3-PUFAs
Jia et al. (2008)
CAC model
Fat-1 mouse
• Reduces tumor size
• Reduces colon shortening
• Reduces distal colon tumorogenesis
• Reduces COX-2 protein expression
• Represses NF-κB transcriptional activation
• Reduces mucosal PGE2 levels
• Preserves tumor suppressive 15-PGDH gene expression
• Reduces proliferation
• Reduces β-catenin nuclear translocation
• Increases apoptosis
• Increases apoptotic molecules FAS and Bax
• Reduces expressions of antiapoptotic molecules survivin 
and Bcl-2
Endogenous conversion of ω6- into 
ω3-PUFAs
Han et al. (2016b)
CAC model
C57BL/6 mouse
• Similar ω3 tissue PUFAs content and ratio of ω6/ω3 than in the fat-1 
mouse
• Do not confirm anti-tumorigenic effects expressed above




• Reduces cell proliferation
• Reduces β-catenin nuclear translocation
• Increases apoptosis
At carcinogenesis initiation and promotion:
• Reduces tumor multiplicity
• Reduces tumor incidence
• Reduces tumor size
• Increases tissue switch from AA to EPA
• Reduces PGE2
• Restores the loss of Notch signaling
• Increases Lactobacillus in gut microbiota 
EPA free fatty acid Piazzi et al. (2014)
Reflux esophagitis 
model
• Reduces esophageal damage
• Reduces inflammation
• Reduces expression of MyD88
• Decreases pro-inflammatory cytokine expression IL-1, IL-8, IL-6
• Increases SOD expression
• Reduces LPO




• Reduces mucosal thickening
• Reduces inflammatory cell infiltration
• Reduces gastric inflammation
• Reduces inflammatory COX-2, IL-1β
• Reduces inflammatory IL-6, IL-8, IFNγ
• Decreases angiogenic growth factors VEGF, PGDF
• Reduces atrophic gastritis and tumorogenesis
• Decreases gastric cancer
• Preserves 15-PGDH expression
Endogenous conversion of ω6- into 
ω3-PUFAs
Han et al. (2016)
ALPI, alkaline phosphatase; ATL, aspirin-triggered lipoxins; AT-Rv, aspirin-triggered resolving; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; CAC, colitis-
associated cancer; COX-2, cyclooxygenase 2; CXCL1/KC, keratinocyte-derived chemokine; DSS, dextran sodium sulfate; FAP, familial adenomatous polyposis; GPx, 
glutathione peroxidase; GR, glutathione reductase; GST, glutathione-S transferase; HDHA, hydroxy docosahexaenoic acid; HDPAn-6, hydroxy-docosahexaenoic acid; HETE, 
hydroxyeicosatetraenoic acid; ICAM-1, intercellular adhesion molecule 1; IFNγ, interferon gamma; IL, interleukin; iNOS, inducible nitric oxide synthase; LFA-1, lymphocyte 
function associated antigen-1; LPO, lipid peroxidation; LX, lipoxin; MaR, maresin; MIP-2, macrophage inflammatory protein 2; MyD88, myeloid differentiation primary 
response gene 88; NF-κB, nuclear factor kappa B; NMU, N-methyl-N-nitrosurea; NPD, neuroprotection; PG, prostaglandin; PGDF, platelet-derived growth factor 15-PGDH, 
15-hydroxyprostaglandin dehydrogenase; PD, protectin; PMN, polymorphonuclear leukocyte; ROS, reactive oxygen species; Rv, resolving; TNBS, trinitrobenzenesulphonic 
acid; SOD, superoxide dismutase; TFF3, trefoil factor 3; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor-α; TX, thromboxane; VCAM1, vascular cell 
adhesion protein 1; VEGF, vascular endothelial growth factor.
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6 August 2019 | Volume 10 | Article 852Frontiers in Pharmacology | www.frontiersin.org
IL-6 in DSS model (Campbell et al., 2010; Ishida et al., 2010). 
Synthetic RvD supplementation has shown to improve colitis 
activity index and reduce body weight loss, colonic damage, 
PMN infiltration, colonic cytokine levels for TNF-α, IL-1β, 
MIP-2, CXCL1/KC, and NF-κB phosphorylation, as well as 
mRNA expression of NF-κB and the adhesion molecules 
VCAM-1, ICAM-1, and LFA-1 in both models. AT-RvD1 
showed greater potency than its precursor 17R-HDHA and 
RvD2 (Bento et al., 2011) (Table 1).
Endogenous MaR1 is also a DHA-derived SPM. Synthetic MaR1 
has shown similar effects to resolvins in both mentioned models. 
The mechanism proposed in DSS model suggests the inhibition 
of the NF-κB pathway and reduction of PMN transmigration 
and  pro-inflammatory mediators like IL-1β and IL-6 (Marcon 
et al., 2013) (Table 1).
Exogenous administration of synthesized PD1n-3DPA or 
RvD5n-3DPA reduced inflammation and improved the score 
of disease in the DSS model too, through a mechanism that 
implies regulation of neutrophil–endothelial interaction and 
reduction of granulocyte trafficking. The impact of PD1n-
3DPA in pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) 
was bigger, and RvD5n-3DPA causes only a partial decrease of 
IL-1β (Gobbetti et al., 2017). Apart from those mediators, 
other DPA-derived metabolites like 17-HDPAn-6 and 10,17-
HDPAn-6, and although in lower degree 17-HDHA, are also 
effective in protecting from DSS colitis (Chiu et al., 2012) 
(Table 1).
Previously mentioned results are consistent with the 
protection from DSS-induced colitis found in a mice model 
that overexpresses the C. elegans fat-1 gene that transforms 
endogenous ω6 into ω3-PUFAs, resulting in elevated tissue levels 
of ω3-PUFAs and increased levels of RvE1, RvD3, and PD1/
NPD1 (Hudert et al., 2006) (Table 1).
In conclusion, exogenous administration of AT analogs and 
synthetic SPMs has proved effective in improving disease and 
inflammatory outcomes in most frequently used IBD animal 
models. Current IBD therapies, based on decreasing signs and 
symptoms, do not eliminate the disease, cause frequent side 
effects, are expensive and inefficient in many patients, and 
cause immunosuppression, like anti-TNFα drugs. Previous 
results suggest that exogenous administration of stable SMPs 
derivates might be an innovative and more secure therapeutic 
approach to control intestinal inflammation, preventing 
CRC development.
OMEGA-3 PUFA SUPPLEMENTATION 
AND DEVELOPMENT OF COLORECTAL 
CANCER AND RELATED DISEASES
The possible beneficial effects of ω3-PUFAs in CRC incidence 
was firstly suggested in 1997 in West Coast fishermen (Schloss 
et al., 1997). Two years later, it was pointed out that several of 
the known risk factors for some cancers, including colon cancer, 
may be reduced by dietary ω3-PUFAs supplementation and 
encouraged the implementation of clinical chemoprevention 
trials (Rose and Connolly, 1999).
Although a positive effect of ω3-PUFAs supplementation has 
been reported in some animal models, controversial results have 
been obtained in DSS and AOM models. EPA supplementation 
in the APCMin/+ mouse model of FAP reported a reduction in 
the number and size of tumors and improvements on weight, 
related to COX-2 inhibition, reductions in β-catenin nuclear 
translocation, and proliferation and increased apoptosis (Hansen 
Petrik et al., 2000; Fini et al., 2010). Later, protective mechanisms 
based on upregulation of superoxide dismutase (SOD) and 
glutathione peroxidase enzymes, reductions on lipid peroxidation 
(LPO), and downregulated activity of pro-angiogenic genes were 
also proposed in N-methyl-N-nitrosurea CRC rat model and 
human colon carcinoma grown in nude mice (Kato et al., 2002; 
Kenar et al., 2008). However, previous studies in DSS model 
have yielded contradictory results when supplemented with fish 
oil rich in ω3-PUFAs or EPA, showing exacerbation of colitis 
(Matsunaga et al., 2008) or, by contrast, improvement of colitis 
scores and inflammatory eicosanoids profile, reductions on LPO, 
ROS levels and PMN infiltration, and increases of antioxidant 
enzymes (Morin et al., 2016; Sharma et al., 2019). More evidence 
on contradictory results comes from the mouse model of colitis-
associated cancer (CAC) generated by a single pretreatment with 
azoxymethane (AOM) and posterior ingestion of DSS. AOM/ 
DSS-induced Fat-1 mouse model showed reduced tumor incidence, 
multiplicity, and size, accompanied by reduction of NF-kB activity, 
iNOS and COX-2 expression, β-catenin nuclear translocation, 
overexpression of the anti-proliferative transforming growth 
factor beta (TGF-β) in colon tissue, reduction of AA-derived 
eicosanoids, and increased apoptosis, whereas similar ω3-PUFAs 
content obtained by DHA supplementation in C57BL/6-AOM/
DSS model fails to confirm these results (Nowak et al., 2007; Jia et 
al., 2008; Han et al., 2016b). EPA-protective effects have been also 
described in non-Fat-1 AOM/DSS model related to restoration of 
Notch signalling and improvement of Lactobacillus gut microbiota 
(Piazzi et al., 2014) (Table 1 and Figure 1).
EPA-supplemented long-standing UC patients in stable 
clinical remission and active inflammation improve endoscopic 
and histologic scores, intestinal epithelial cell differentiation and 
turnover, and module gut microbiota composition (Prossomariti 
et al., 2017), whereas some controversial results have been found 
between ω3-PUFAs and risk of CRC in prospective studies 
evaluating fish intake. A meta-analysis of 22 prospective cohorts 
and 19 case–control studies found in 2012 an overall 12% CRC 
risk reduction, being more pronounced for rectal cancer (Wu et al., 
2012). In 2014, another meta-analysis including 60,627 individuals 
from prospective and case–control studies showed an opposite 
association between ω3-PUFAs tissue levels, especially EPA and 
DHA, and CRC risk (Yang et al., 2014). A study including 68,109 
Washington residents found dependence of sex and anatomic 
subsite, with reduced risk by fish oil supplementation only in 
men and in colon cancer but not in rectal cancer (Kantor et al., 
2014). A later meta-analysis of 14 prospective studies in 2015, 
including 8,775 patients, found no overall association between 
ω3-PUFAs intake and CRC risk, in spite of observing a tendency 
to reduced risk in proximal region and increase in distal location of 
the colon (Chen et al., 2015). Although controversial results have 
been found between PUFAs intake and risk of CRC in prospective 
ω3-PUFAs in the Gastrointestinal TractIrún et al.
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studies evaluating fish intake, supplementation with fish oil rich 
in ω3-PUFAs has shown to reduce cell proliferation in rectal 
mucosa of patients with sporadic CR adenomas (Anti et al., 1992; 
Anti et al., 1994) and/or to increased mucosal apoptosis (Cheng 
et al., 2003; Courtney et al., 2007). Probably the best evidence of 
ω3 supplementation comes from a randomized trial in FAP that 
found a significant reduction of adenomas incidence (West et al., 
2010). The seAFOod Polyp Prevention trial has just concluded 
FIGURE 1 | Fish oil or ω3 polyunsaturated fatty acids (ω3-PUFAs) supplementation actions on gastrointestinal diseases. (A) Results found in animal models. 
(B) Results in human diseases.
ω3-PUFAs in the Gastrointestinal TractIrún et al.
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that after a year of treatment with EPA and aspirin, the risk of 
having at least one adenoma is not reduced, but both agents show 
chemopreventive activity on colorectal adenoma total burden, 
being EPA more effective in the left colorectum conventional 
adenomas and aspirin in the right colon, particularly for serrated, 
but also for conventional, adenomas (Hull et al., 2018) (Figure 1).
In relation with surgery, ω3-supplementation during 7  days 
prior to or after CRC resection reported beneficial effects 
meanly interfering with inflammatory and immune responses 
(Liang et al., 2008; Sorensen et al., 2014). Finally, beneficial 
effects of EPA supplementation have also been found in patients 
undergoing liver resection for CRC liver metastases, showing 
reduced vascularity and increased overall survival during the 
first 18 months after resection, although without changes in 
recurrence rate (Cockbain et al., 2014) (Figure 1).
As colon cancer is particularly resistant to current 
chemotherapeutic drugs, the role of ω3-PUFAs supplementation 
as part of an adjuvant therapeutic strategy in colon cancer 
treatment was soon proposed in order to check their influence in 
drug toxicity and selectivity. In this way, DHA revealed to be able 
to selectively target nucleoside analogue arabinosylcytosine (araC) 
toxicity toward colonic tumor cells without affecting the normal 
cells in vitro (Cha et al., 2005). Similar results were found in rats 
bearing Ward colon tumor under a cyclical regimen of CPT-11/5-
fluorouracil (5-FU) where supplementation with fish oil inhibited 
tumor growth by raising its chemo-sensitivity and thus decreasing 
body weight loss, anorexia, and muscle wasting (Xue et al., 2009). 
Another study has proved the influence of EPA supplementation 
on the radio-sensitivity of colon adenocarcinoma cells HT-29 by 
increasing the extent of the LPO caused by radiation (Manda et al., 
2011). CRC patients under chemotherapy enrolled in a prospective 
randomized fish oil supplementation and placebo-controlled 
study showed reduced CRP/albumin ratio, without changes in 
inflammatory cytokine profile, suggesting a reduction in the rate 
of development inflammatory and nutritional complications, and 
limiting the weight loss, suggesting that supplementation with 
these compounds is advisable during CRC treatment (Mocellin et 
al., 2013) (Figure 1).
SPMS IN COLORECTAL CANCER 
AND RELATED DISEASES
SPMs production in the gut is crucial for maintaining homeostasis, 
and a failure of colonic mucosa to produce adequate anti-
inflammatory LMs can explain the persistent colonic inflammation 
in UC. Colon biopsies have shown important reductions or no 
detectable production of LXA4 and increased proinflammatory 
LTB4, PGE2, and TXB2 in IBD patients, probably due to decreased 
15-LOX-2 enzyme expression, despite an apparent up-regulation 
of the resolving and protecting pathways from the ω-3 DPA 
metabolome. Innovative therapies based on SPMs DPA-derived 
or aspirin use in order to maintain the capacity to synthesize 
colonic 15-epi-LXA4 from AA by acetylated COX2/5-LOX have 
been suggested as good strategies to reduce clinical signs in IBD 
(Mangino et al., 2006; Gobbetti et al., 2017). A recent report has 
also found that commercial RvE1 inhibits the oncoprotein c-Myc 
expression, overexpressed in a large variety of human cancers, 
and also in CAC model, which causes more tumor aggression 
and poor clinical outcomes (Nesbit et al., 1999; Beroukhim et 
al., 2010) in normal human colon epithelial cells stimulated with 
TNFα and also in HCT116 human colon cells (Zhong et al., 
2018). Another recent study has pointed out that chemotherapy 
generates tumor cell debris, which stimulates tumorigenesis by 
the release of pro-inflammatory cytokines by macrophages, and 
that commercial RvE1, RvD1, and RvD2 can turn macrophages 
from pro-inflammatory/tumorigenic to a phagocytic phenotype, 
causing clearance of tumor cell debris and then preventing 
tumor recurrence (Sulciner et al., 2018). In colorectal adenoma 
recurrence, a randomized trial of aspirin did not found association 
between plasma levels of LXA4 and RvD1 and the risk of adenoma 
recurrence despite their previously mentioned anti-inflammatory 
and pro-resolving actions (Fedirko et al., 2017).
Although a large number of studies correlate the effect of EPA 
in pro-inflammatory mediator synthesis via COX-2 inhibition, 
it must be said that there is a lack of studies about the situation 
of SPMs in CRC despite the reported deficiency in one of the 
enzymes with a strong participation on its production, 15-LOX-
1, as the largest contributor to the CRC (Shureiqi et al., 2000; 
Shureiqi et al., 2005).
EFFECT OF ω3-PUFAS ON 
INFLAMMATION-BASED CANCERS OF 
THE UPPER GASTROINTESTINAL TRACT
Gastroesophageal reflux disease (GERD) is a chronic disease 
caused by the reflux into the esophagus of acid, bile salts, and 
other noxious agents contained in gastric juice, which induces an 
inflammatory response and damage of the esophageal epithelium. 
Complications of reflux esophagitis include the development of 
ulcers and structures or Barrett’s esophagus (BE), which is defined 
by the replacement of the normal squamous epithelium by an 
intestinal type metaplastic epithelium, which is a preneoplastic 
condition predisposing to esophageal adenocarcinoma (Souza, 
2017). The effect of PUFAs has been evaluated in esophagitis, 
Barrett’s metaplasia, and established adenocarcinoma. Thus, in an 
experimental model of reflux esophagitis in rats, intraperitoneal 
administration of a 10% ω3-fish oil-based lipid emulsion 
significantly decreased esophageal damage and inflammation, 
whereas administration of a 10% ω6-soybean oil-based lipid 
emulsion increased the damage (Zhuang et al., 2016). This model is 
associated with an increased expression of myeloid differentiation 
primary response gene 88 (MyD88), the proinflammatory 
cytokines IL-6, IL-8, and IL-1β, and oxidative stress. Interestingly, 
the authors found the lowest levels of proinflammatory mediators 
in the ω3-PUFAs-treated animals, whereas the ω6-PUFAs group 
showed the highest. Both ω3 and ω6-PUFAs reduced the levels 
of malondialdehyde, a marker of LPO, but the decrease was 
more pronounced in the ω3-PUFA group, which could be due 
to an increase in SOD expression, an effect that was exclusive of 
ω3-PUFAs treatment. A community-based study reported an 
inverse association between the intake of ω3-fatty acids and the 
risk of BE, where those who consumed the highest amount were 
ω3-PUFAs in the Gastrointestinal TractIrún et al.
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at less than half the risk of developing BE and three times lower 
the risk to have a long segment BE than those who consumed 
the lowest amount (Kubo et al., 2009). In a human intervention 
study, dietary supplementation with 1.5 g/day unesterified EPA for 
6 months in patients with BE significantly changed ω3-fatty acid 
concentrations in Barrett’s mucosa and reduced COX-2 protein 
expression, although without repercussion on PGE2 levels and 
cellular proliferation (Mehta et al., 2008). PUFAs also might have a 
role as adjuvant therapy in established esophageal adenocarcinoma 
since ω3-PUFAs EPA and DHA have shown anti-proliferative 
effects on esophageal adenocarcinoma cell lines (Eltweri et al., 
2018). A phase II clinical trial in patients with advanced esophago-
gastric adenocarcinoma receiving palliative platinum-based 
chemotherapy showed that the addition of an intravenous infusion 
of omega ω3-PUFAs as a 10% fish oil lipid emulsion once weekly 
reduced chemotherapy-related toxicity and improved radiological 
response (Eltweri et al., 2019) (Table 1, Figure 1).
In the stomach, H. pylori infection is the main risk factor for 
both gastritis and gastric carcinoma. It is considered to be the 
initiator of a chronic inflammatory response that contributes 
to the development of gastric cancer (Park et al., 2015). There 
is some evidence suggesting a protective effect for ω3-PUFAs 
against H. pylori-associated gastric carcinogenesis. Recent studies 
have reported that ω3-PUFAs could have antimicrobial activity 
against H. pylori, inhibiting its growth and colonization of gastric 
mucosa (Correia et al., 2012). Fat-1 transgenic mice overexpress 
n-3 desaturase, leading to abundant ω3-PUFAS with reduced 
levels of ω6-fatty acids in their organ and tissues without a dietary 
ω3 supply. Using a model of gastric tumorigenesis induced by H. 
pylori infection and high salt diet, Han et al. found that Fat-1 mice 
were protected against H. pylori-induced inflammation, chronic 
atrophic gastritis, and the development of gastric carcinoma 
compared to wild type mice (Han et al., 2016). Moreover, the 
expression of inflammatory and angiogenic growth factors such 
as COX-2, IL-1β, VEGF, and PDGF was significantly decreased 
in Fat-1 mice. The authors estimated dietary intake of ω3-PUFAs 
of more than 0.5 g/60 kg to achieve lipid profile similar to that of 
Fat-1 mice. This study provides relevant preclinical evidence of the 
effect of ω3-PUFAs on H. pylori-induced gastric carcinogenesis 
and the dose necessary to achieve it (Table 1, Figure 1).
CONCLUSIONS AND POTENTIAL FUTURE 
DEVELOPMENTS
Although research on the role of ω3-PUFAs and SPMs on 
inflammation and cancer is rising continuously and seems to 
indicate a general positive effect of supplementation on colorectal, 
esophageal, and gastric cancers, larger efforts should be made 
to perform high-quality randomized control trials to establish 
their mechanisms of action, the best timing on supplementation, 
dosage, source of these products, way of extraction, preparation 
and quantification, and well-suited nutritional questionnaires to 
obtain the biggest efficacy, which will allow us to set the use of 
these compounds in clinical guidelines for cancer prevention.
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